Latest News
MS disease modifying therapy, Aubagio® (teriflunomide), to be delisted on the 1st October 2021
Pharmaceutical company Sanofi have advised that their MS disease modifying therapy (DMT), Aubagio (generic name, teriflunomide), will be delisted from the Australian market from approximately the 1st October 2021, exact date pending.
- This decision has been made as the market for...
Major funding boost for MS research
MS Australia has today received a major funding boost of $7.4 million from MSWA, this is the largest single donation received by MS Australia from any donor. This funding will allow essential research projects underway in WA to continue, while most of the funds will be directed to the expansion...
Scheduling and recording your COVID-19 vaccination
The COVID-19 vaccination program began rolling out in gradual phases from February 2021, targeting specific groups of people in higher risk categories first, including...
Partnership grant to improve decisions about accessing stem cell-based therapies
- A team of Australian researchers and disease-based charities including MS Australia have banded together to promote and simplify access to evidence-based stem cell therapies in Australia.
- The team has now received nearly $800,000 from the Medical Research Future Fund to...
MS subtypes: What's in a name?
-
MS is traditionally split into subtypes: relapsing-remitting (RRMS), secondary-progressive (SPMS), primary-progressive (PPMS) and progressive-relapsing (PRMS), based on how the disease is manifesting.
-
In this study, scientists used machine learning to classify MS into...
Health behaviours in MS: Impact of the Australian bushfires and the COVID-19 pandemic
- The Black Summer Australian bushfires of 2019/2020 were closely followed by the COVID-19 pandemic in 2020, threatening Australian communities in many ways within a short time frame.
- People with disabilities, such as MS, can be more greatly impacted by disasters and crises than the...
MS risk and relapses: Unlocking new clues from our genes
- Two new studies investigated MS genetics to discover new clues to explain the pathology of the disease.
- The first study examined how the genes that affect the risk of developing MS can change the brain and the immune system.
- The second study looked for genes that affect...
A note from our CEO: Rohan Greenland - July
Work has begun in earnest this month on developing a new strategic plan for MS Australia and its recently amalgamated subsidiary, MS Research Australia - and we need your help to do it!
The strategic plan will be the first for the combined entity that is the new MS Australia,...
NDIS independent assessments won't proceed
Minister for the NDIS, Linda Reynolds, has confirmed that the NDIS will not proceed with introducing independent assessments. This is welcome news for people with MS, other disabilities, advocates, service providers and numerous others who have expressed their concern about this reform over the...
Prioritising the MS research and advocacy agenda – have your say!
MS Australia is inviting the MS community to take part in an online survey about MS research and advocacy priorities.
The views of the Australian MS community are integral in guiding the strategic...
Pregnancy and modern MS therapies
- A new study of over 1600 women looked at the effect of modern MS therapies on relapses before, during and after pregnancy.
- The study found that continuing the medication natalizumab (Tysabri) into pregnancy reduced the relapse risk during pregnancy. Restarting the medication soon...
World Continence Week 2021
World Continence Week 2021 may have finished but the topic remains as important as ever. We know that bladder and/or bowel issues are a concern for many people living with MS.
For those who didn’t see it, here is a two-part article we collaborated on with...